C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 99 filers reported holding C4 THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.06 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $302,605 | -3.9% | 65,499 | +70.0% | 0.00% | – |
| Q1 2024 | $314,839 | -91.9% | 38,536 | -94.4% | 0.00% | -100.0% |
| Q4 2023 | $3,910,263 | +3628.1% | 692,082 | +1127.3% | 0.00% | – |
| Q3 2023 | $104,887 | -31.8% | 56,391 | +0.9% | 0.00% | – |
| Q2 2023 | $153,753 | -29.5% | 55,910 | -19.5% | 0.00% | – |
| Q1 2023 | $218,101 | +127.8% | 69,459 | +328.1% | 0.00% | – |
| Q4 2022 | $95,733 | -32.6% | 16,226 | -0.2% | 0.00% | – |
| Q3 2022 | $142,000 | +35.2% | 16,256 | +17.3% | 0.00% | – |
| Q2 2022 | $105,000 | -96.9% | 13,855 | -90.0% | 0.00% | -100.0% |
| Q1 2022 | $3,358,000 | -77.5% | 138,412 | -70.2% | 0.00% | -75.0% |
| Q4 2021 | $14,948,000 | -28.9% | 464,202 | -1.3% | 0.00% | -20.0% |
| Q3 2021 | $21,023,000 | +18.4% | 470,523 | +0.2% | 0.01% | +25.0% |
| Q2 2021 | $17,761,000 | -21.2% | 469,395 | -23.0% | 0.00% | -33.3% |
| Q1 2021 | $22,553,000 | +126.5% | 609,719 | +102.9% | 0.01% | +100.0% |
| Q4 2020 | $9,957,000 | – | 300,542 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 6,880,527 | $31,788,035 | 11.47% |
| Soleus Capital Management, L.P. | 4,051,996 | $18,720,222 | 1.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,442,841 | $6,665,925 | 1.57% |
| COMMODORE CAPITAL LP | 3,410,384 | $15,755,974 | 1.08% |
| TCG Crossover Management, LLC | 1,276,574 | $5,897,772 | 0.62% |
| Bain Capital Life Sciences Investors, LLC | 1,111,910 | $5,137,024 | 0.56% |
| RA Capital Management | 4,878,000 | $22,536,360 | 0.30% |
| Atom Investors LP | 332,620 | $1,536,704 | 0.15% |
| Orbimed Advisors | 1,513,058 | $6,990,328 | 0.14% |
| WASATCH ADVISORS LP | 4,847,150 | $22,393,833 | 0.12% |